vertex report sales/earn provid busi updat
investor yesterday announc select next-
gen corrector advanc two phase triplet combo trial
respect strong sale earn consensu
opco partial help pull-in
previous note start consist beat sales/earn
expect evidenc quarter select two triplet therapi
strong phase data initi phase trial imminentwith readout
earli tee well stay bullish
select two next-gener corrector import clear
event compani accru enough efficaci safeti
data make inform decis regard risk/benefit profil
chosen compound phase test especi import given fast-
develop strategi pursu
risk/benefit profil appear close ideal
efficaci line with/bett gold-standard cf medic kalydeco
safeti profil seem benign await in-depth data
phase trial medic confer initi read posit especi
light current price concern around rare diseas
point investor put strong among
best-perform stock year strong sales/
earn upgrad tez/iva launch well-anticip physician
commun orkambi kalydeco keep benefit label expans
recent complet survey high-prescrib pulmonologist
struck potenti bolu effect tez/iva launch pdufa
combin satisfact regard patient control orkambi
survey hasin viewvalid manag strategi
import light disappoint orkambi launch
street seem focus triplet therapi hetmin/homozyg
patient point like midst sales/earn
upgrad cycl also note consensu thesi proven
incorrect survey work mani lever pull give
us greater certainti time chang estim base manag
commentari adjust cog estim slightli lower gm assumpt
global biotechnolog
compani aim discov develop
commerci innov medicin
peopl seriou diseas lead
analyst certif import disclosur see disclosur appendix
orkambi achiev patient penetr homozyg
tez/iva success approv get
homozyg penetr
slower expect eu launch orkambi franc
price
triplet mid-stag clinic trial news flow
rate vertex outperform price target
compani posit deliv strong sale earn
growth next five year potenti even
greater growth near- tezacaftor/ivacaftor mid-term triplet
therapi homozyg cf patient
product launch outperform opex reach steadi state
could begin upsid stori
orkambi reimburs approv variou eu row
tez/iva doublet approv homozyg us
triplet in-depth phase data
initi pivot develop triplet regimen
one once/day arm
vertex secur broad reimburs cf franchis ex-u
rapidli expect
tez/iva sale ramp faster expect
triple-combin regimen tez/iva plu anoth corrector
approv market hetmin popul
disclos addit pipelin opportun
failur secur orkambi regulatori approv australia
reimburs europ canada australia near term
lower expect uptak orkambi/tez/iva
compet regimen other abbvie/galpago
approv earlier expect take signific market share
util composit valuat methodolog biotechnolog compani util forward price-to-earnings multipl net present valu
adjust estim earn sinc biotech sector high-growth/high-expect sector aim rank target compani base
qualiti sale and/or earn growth versu peer group peer index nbi expect earn
growth next three five year well expect higher termin multipl due
perceiv greater certainti qualiti sales/earn growth appli discount rate vs peer group averag
risk outperform rate slow orkambi sale failur secur fda approv tezacaftor/ivacaftor combo
disappoint commerci launch penetr tezacaftor/ivacaftor pipelin failur doublet triplet and/or regulatori
non-approv kalydeco label extens
statement oper varianceproduct revenu product develop gener administr asset impair cost expens loss oper incom expens incom expens loss provis benefit incom tax benefit incom incom loss incom loss attribut vertex outstand outperform
exhibit absolut chang lung function phase
exhibit chang sweat chlorid phase
exhibit chang lung function phase
exhibit chang sweat chlorid phase
exhibit potenti market share tez/iva residu function mutat
compani present intend report total cf product revenu guidanc upon tez/iva approv
statement revenu royalti collabor total product royalti research develop sale gener administr restructur expenses- intang asset impair total cost expens incom loss oper interest incom net- interest expens net- incom expens incom loss provis benefit incom tax provis benefit incom net incom loss net incom loss attribut vertex dilut share outstand sale oper outperform
